Skip to Content
Blockchain

Drugmakers Think Blockchains Could Improve Clinical Trials

January 9, 2018

Three big pharmaceutical firms—Pfizer, Amgen, and Sanofi—are working together to use blockchains to speed up clinical tests of new drugs, according to CoinDesk.

The problem: Patient data that’s crucial to locating individuals for clinical trials is usually scattered across multiple proprietary systems that are often incompatible with each other. That can make it hard to recruit for trials.

How blockchains could help: A distributed ledger could allow individual patients to store data anonymously and make it visible to trial recruiters, who could then reach out to individuals who meet the eligibility criteria for a given trial. It could also streamline communication between doctors and patients during the trial.

It’s still early: Technologists are still mostly experimenting with blockchain-based medical records systems, and big technical challenges remain. The health-care industry is also heavily regulated and tends to be risk averse, which could impede adoption.

Keep Reading

Most Popular

This new data poisoning tool lets artists fight back against generative AI

The tool, called Nightshade, messes up training data in ways that could cause serious damage to image-generating AI models. 

The Biggest Questions: What is death?

New neuroscience is challenging our understanding of the dying process—bringing opportunities for the living.

Rogue superintelligence and merging with machines: Inside the mind of OpenAI’s chief scientist

An exclusive conversation with Ilya Sutskever on his fears for the future of AI and why they’ve made him change the focus of his life’s work.

How to fix the internet

If we want online discourse to improve, we need to move beyond the big platforms.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at customer-service@technologyreview.com with a list of newsletters you’d like to receive.